Axial Biotech Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Axial Biotech Inc.
Seventure Reaffirms Microbiome Confidence With New €200m Fund
With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.
Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin
Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.
Appointments: Almirall, Axial, Therachon, Theranexus, Carrick and Karolinksa
This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial, Therachon, Theranexus and Karolinska.
Deals in Depth: August 2012
GSK sold to Aspen Global a group of products in Australia for $270 million. PE firm Cinven paid $730 million for branded and generics company Mercury Pharma. Debt offerings overwhelmingly were the most popular method of financing in both biopharma and device industries.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice